There's more here than meets the eye... Those of us who've been here awhile remember the day Theralase patented over 10,000 ruthenium and associated PDC compounds to address the many faces of cancer... and so much more.
When I had the chance to talk to Dr. Sherri McFarland briefly during her lecture at U.B.C. years ago, she wasn't even that excited about our Ru based compunds any more... and look at how successful they are in both safety AND efficacy.
No, she was on about her work on osmium based compounds, which are expected to be most efficacious in treating glioblastoma... Why?
Because they cross the blood-brian barrier. How can PDC's work against brain cancers if they can't be absorbed by them?
The osmium-based compounds covered by TLT's patents are potentially the world's only PDC that will be able to fight this horrendous cancer, which every telecom company wants cured... or face the billions of dollars of lawsuits that are burgeoning in their future.
We've been excited about the results in bladder cancer, but TLT has so many other arrows in its quiver...
Makes shareholders like me look forward to seeing the multi-sku'd anti-cancer, anti-viral, modern, Canadian Pharma-Tech that will revolutionize pharma while saving flagging healthcare models all over the world!
GLTA!